Posts by: Margarida Azevedo, MSc

Margarida Azevedo, MSc

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

March 25, 2020March 25, 2020

IPF Carries ‘Substantial Economic Burden’ in US, Study Reports

News

Idiopathic pulmonary fibrosis (IPF) is associated with a substantial economic burden in the United States, especially for patients who require hospitalization, intensive care, or a lung transplant, a study ... Read more

March 17, 2020March 17, 2020

Pulmonary Fibrosis Increases Heart Disease Risk, Real-world Data Suggest

News

Patients with interstitial lung disease (ILD), including pulmonary fibrosis (PF), have an increased risk of coronary heart disease and heart attack, compared to those without these lung conditions, a ... Read more

March 16, 2020March 16, 2020

CRV431 Reduced Fibrosis Markers in IPF Lung Tissue, Hepion Reports

News

Hepion Pharmaceuticals‘ CRV431 has a similar, or even greater effect in reducing markers of idiopathic pulmonary fibrosis (IPF) in lung tissue, compared with standard-of-care IPF treatment, the company reported. ... Read more

February 25, 2020February 25, 2020

FibroKine, Potential PF Treatment Strategy, Gets $250,000 CSL Behring Research Grant

News

Researchers at the University of Pittsburgh and the University of Delaware received funding for their research into innovative therapies for specific disease areas, including pulmonary fibrosis (PF). CSL Behring and the University ... Read more

February 14, 2020February 14, 2020

Paragonix’s LUNGguard System Cleared by FDA for Use in Transporting Donor Lungs

News

The U.S. Food and Drug Administration (FDA) has cleared Paragonix Technologies’ request that LUNGguard, its preservation system for transporting donor lungs, for commercial use. The request came as a premarket notification ... Read more

May 20, 2016May 20, 2016

Veracyte Presents Promising Data on a Genomic Test to Accurately Diagnosis IPF

News

Veracyte, Inc., presented new data indicating that its in-development genomic test, the Envisia classifier, has the potential to diagnosis idiopathic pulmonary fibrosis (IPF), distinguishing it from other interstitial lung diseases (ILD), and ... Read more

May 13, 2016May 13, 2016

Veracyte to Present Data on Diagnostic Tests for IPF and Lung Cancer at ATS 2016

News

Veracyte, Inc., recently announced that data from multiple studies supporting the ability of its diagnostic tests to help detect pulmonary disease, including idiopathic pulmonary fibrosis (IPF), will be presented at the American Thoracic ... Read more

May 9, 2016May 9, 2016

ProterixBio, New Name for BioScale, to Focus on Diagnostics for IPF and Other Pulmonary Ailments

News

ProterixBio, Inc., is the new name for the company previously known as BioScale, Inc., reflecting a change in strategy. Whereas BioScale had focused on care management solutions for pulmonary and ... Read more

April 27, 2016April 28, 2016

Researchers Find Pulmonary Fibrosis and COPD Share a Common Genetic Network

News

Researchers at Yale School of Medicine, Boston University School of Medicine, and other institutions applied an integrative genomic approach to study chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary ... Read more

March 16, 2016March 16, 2016

IPF Drug in Phase 2 Study Reduced Lung Fibrosis, Improved Function in 35% of Patients

News

FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated ... Read more